Findings from a prospective phase II trial in 300 men with ≤cT2b, Gleason score 6 or 7, treatment-naive prostate cancer demonstrate the safety and efficacy of permanent-seed implantation brachytherapy without hormonal therapy. Ten biochemical failures occurred and one patient died of prostate cancer. The median 5-year PSA level was 0.01 ng/ml and 5-year overall survival was 94.9%. Most men (>90%) were “satisfied or extremely satisfied” at 2 years and 4 years after implantation.
References
Frank, S. J. et al. Prospective phase II trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes. Int. J. Radiat. Oncol. Biol. Phys. http://dx.doi.org/10.1016/j.ijrobp.2017.09.050 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. Brachytherapy monotherapy is efficacious. Nat Rev Urol 14, 700 (2017). https://doi.org/10.1038/nrurol.2017.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.195